Literature DB >> 21385850

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Davide Bagnara1, Matthew S Kaufman, Carlo Calissano, Sonia Marsilio, Piers E M Patten, Rita Simone, Philip Chum, Xiao-Jie Yan, Steven L Allen, Jonathan E Kolitz, Sivasubramanian Baskar, Christoph Rader, Hakan Mellstedt, Hodjattallah Rabbani, Annette Lee, Peter K Gregersen, Kanti R Rai, Nicholas Chiorazzi.   

Abstract

Chronic lymphocytic leukemia (CLL) is an incurable adult disease of unknown etiology. Understanding the biology of CLL cells, particularly cell maturation and growth in vivo, has been impeded by lack of a reproducible adoptive transfer model. We report a simple, reproducible system in which primary CLL cells proliferate in nonobese diabetes/severe combined immunodeficiency/γc(null) mice under the influence of activated CLL-derived T lymphocytes. By co-transferring autologous T lymphocytes, activated in vivo by alloantigens, the survival and growth of primary CFSE-labeled CLL cells in vivo is achieved and quantified. Using this approach, we have identified key roles for CD4(+) T cells in CLL expansion, a direct link between CD38 expression by leukemic B cells and their activation, and support for CLL cells preferentially proliferating in secondary lymphoid tissues. The model should simplify analyzing kinetics of CLL cells in vivo, deciphering involvement of nonleukemic elements and nongenetic factors promoting CLL cell growth, identifying and characterizing potential leukemic stem cells, and permitting preclinical studies of novel therapeutics. Because autologous activated T lymphocytes are 2-edged swords, generating unwanted graph-versus-host and possibly autologous antitumor reactions, the model may also facilitate analyses of T-cell populations involved in immune surveillance relevant to hematopoietic transplantation and tumor cytoxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385850      PMCID: PMC3109718          DOI: 10.1182/blood-2010-12-324210

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells.

Authors:  L Lagneaux; A Delforge; C De Bruyn; M Bernier; D Bron
Journal:  Leuk Lymphoma       Date:  1999-11

Review 2.  CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes.

Authors:  S Deaglio; R Mallone; G Baj; A Arnulfo; N Surico; U Dianzani; K Mehta; F Malavasi
Journal:  Chem Immunol       Date:  2000

3.  MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

Authors:  A Stacchini; M Aragno; A Vallario; A Alfarano; P Circosta; D Gottardi; A Faldella; G Rege-Cambrin; U Thunberg; K Nilsson; F Caligaris-Cappio
Journal:  Leuk Res       Date:  1999-02       Impact factor: 3.156

4.  Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells.

Authors:  L Lagneaux; A Delforge; D Bron; C De Bruyn; P Stryckmans
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

5.  Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera.

Authors:  A Shimoni; H Marcus; B Dekel; R Shkarchi; F Arditti; L Shvidel; M Shtalrid; W Bucher; A Canaan; D Ergas; A Berrebi; Y Reisner
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

6.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

7.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

Authors:  F Fais; F Ghiotto; S Hashimoto; B Sellars; A Valetto; S L Allen; P Schulman; V P Vinciguerra; K Rai; L Z Rassenti; T J Kipps; G Dighiero; H W Schroeder; M Ferrarini; N Chiorazzi
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

Review 8.  Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model.

Authors:  Brian J Scaglione; Erica Salerno; Murugabaskar Balan; Frederick Coffman; Pablo Landgraf; Fatima Abbasi; Sergei Kotenko; Gerald E Marti; Elizabeth S Raveche
Journal:  Br J Haematol       Date:  2007-10-17       Impact factor: 6.998

9.  Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Authors:  Sivasubramanian Baskar; Ka Yin Kwong; Thomas Hofer; Jessica M Levy; Michael G Kennedy; Elinor Lee; Louis M Staudt; Wyndham H Wilson; Adrian Wiestner; Christoph Rader
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

10.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Authors:  Piers E M Patten; Andrea G S Buggins; Julie Richards; Andrew Wotherspoon; Jon Salisbury; Ghulam J Mufti; Terry J Hamblin; Stephen Devereux
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

View more
  88 in total

1.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

Review 2.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

Review 3.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

4.  Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Authors:  Jan A Burger; Mariela Sivina; Nitin Jain; Ekaterina Kim; Tapan Kadia; Zeev Estrov; Graciela M Nogueras-Gonzalez; Xuelin Huang; Jeffrey Jorgensen; Jianling Li; Mei Cheng; Fong Clow; Maro Ohanian; Michael Andreeff; Thomas Mathew; Philip Thompson; Hagop Kantarjian; Susan O'Brien; William G Wierda; Alessandra Ferrajoli; Michael J Keating
Journal:  Blood       Date:  2018-12-07       Impact factor: 22.113

Review 5.  Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

6.  Signal-dependent and signal-independent functions of the B-cell receptor in chronic lymphocytic leukemia.

Authors:  Dimitar G Efremov; Stefania Gobessi
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

7.  Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.

Authors:  Qingsong Yin; Mariela Sivina; Harlan Robins; Erik Yusko; Marissa Vignali; Susan O'Brien; Michael J Keating; Alessandra Ferrajoli; Zeev Estrov; Nitin Jain; William G Wierda; Jan A Burger
Journal:  J Immunol       Date:  2017-01-11       Impact factor: 5.422

8.  Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.

Authors:  A Vardi; E Vlachonikola; M Karypidou; E Stalika; V Bikos; K Gemenetzi; C Maramis; A Siorenta; A Anagnostopoulos; S Pospisilova; N Maglaveras; I Chouvarda; K Stamatopoulos; A Hadzidimitriou
Journal:  Leukemia       Date:  2016-11-25       Impact factor: 11.528

9.  TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Authors:  Adrian Wiestner; Sarah E M Herman; Eman L Dadashian; Erin M McAuley; Delong Liu; Arthur L Shaffer; Ryan M Young; Jessica R Iyer; Michael J Kruhlak; Louis M Staudt
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

Review 10.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.